Media
Press center
Dr. Yong YUE, CMO of Laekna, Will Attend the SABCS 2023 and Announce the Phase Ib Study Data of Afuresertib in Breast Cancer
2023-11-20
Page Views：1346
Author：Laekna
Source：Laekna
Media Contact
e-mail:communication@laekna.com
Recommendation
-
2026-04-15Positive Topline Results | Laekna’s Phase III Clinical Trial of LAE002 (afuresertib) for Breast Cancer Met Primary Endpoint
More -
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
More
x
RSS Subscription
To stay informed about Laekna, fill out the form below to subscribe.
关注 来凯医药 领英公众号
Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号-2 Privacy Policy 公安备案号：31011502019120sitemap
